Edition:
India

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

46.73USD
13 Dec 2017
Change (% chg)

$0.98 (+2.14%)
Prev Close
$45.75
Open
$45.83
Day's High
$47.05
Day's Low
$44.10
Volume
484,744
Avg. Vol
723,382
52-wk High
$63.33
52-wk Low
$17.52

Summary

Name Age Since Current Position

Howard Pien

59 2014 Independent Chairman of the Board

Hans Bishop

52 2013 President, Chief Executive Officer, Director

Sunil Agarwal

47 2017 President of Research & Development

Steven Harr

46 2014 Chief Financial Officer, Head of Corporate Development

Hyam Levitsky

54 2015 Executive vice president - Research, chief scientific officer

Robert Azelby

49 2015 Executive Vice President, Chief Commercial Officer

Ann Lee

2017 Executive Vice President - Technical Operations

Patrick Yang

69 2017 Executive Vice President

Bernard Cassidy

62 2014 General Counsel, Secretary

Hal Barron

54 2014 Independent Director

Jay Flatley

64 2017 Director

Richard Klausner

65 2013 Director

Rupert Vessey

52 2017 Director

Thomas Daniel

63 2017 Independent Director

Anthony Evnin

76 2014 Independent Director

Robert Nelsen

53 2013 Independent Director

Mary Wilderotter

62 2014 Independent Director

Biographies

Name Description

Howard Pien

Mr. Howard H. Pien serves as a Independent Chairman of the Board of Juno Therapeutics Inc., since January 2014 and as its chairman since September 2014. Mr. Pien is also the chairman of Indivior PLC, which was a division of the United Kingdom-based consumer goods conglomerate Reckitt Benckiser Group plc that was spun off as a public company in December 2014. He also currently serves as a member of the boards of directors of Immunogen, Inc. and Sage Therapeutics, Inc. Mr. Pien previously served as president and chief executive officer and chairman of the board of directors of Medarex, Inc., a biopharmaceutical company, from June 2007 until its acquisition by Bristol-Myers Squibb in September 2009. Mr. Pien served as chief executive officer and chairman of the board of Chiron Corporation, a biotechnology company, from April 2004 until its acquisition by Novartis Corporation in 2006. Mr. Pien has been a director of several other boards, including at ViroPharma, Inc., where he served as its lead independent director from December 2008 to January 2014, Vanda Pharmaceuticals, Inc., and Ikaria, Inc. Mr. Pien also previously served as a director of the Biotechnology Industry Association and the Pharmaceutical Research and Manufacturers of America. Mr. Pien received a B.S. from the Massachusetts Institute of Technology in 1979 and an M.B.A. from Carnegie-Mellon University in 1981.

Hans Bishop

Mr. Hans Edgar Bishop serves as President, Chief Executive Officer, Director of Juno Therapeutics Inc., since September 2013. Bishop previously served as chairman of the board of Genesis Biopharma, Inc., a biotechnology company, from January 2012 until November 2012, and as a member of the board of directors of Avanir Pharmaceutics, Inc., a publicly-traded biopharmaceutical company, from May 2012 to January 2015, when Avanir was sold to Otsuka Pharmaceuticals Co., Ltd. From February 2012 until October 2012, Mr. Bishop was the chief operating officer of Photothera Inc., a late-stage medical device company owned by Warburg Pincus, and he continued working with Warburg Pincus as an Executive in Residence until October 2013. Prior to joining Photothera Inc., Mr. Bishop served as executive vice president and chief operating officer at Dendreon Corporation, a publicly-traded biopharmaceutical company, from January 2010 to September 2011. Mr. Bishop has also served as the president of the specialty medicine business at Bayer Healthcare Pharmaceuticals Inc. from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology and hematology products. Mr. Bishop was employed by Chiron Corporation, a global biotechnology company, from January 2004 to August 2006, with commercial responsibilities that included service as its senior vice president of global commercial operations until its sale to Novartis Corporation. Mr. Bishop received a B.Sc. in Chemistry from Brunel University in London in 1987. Based on Mr. Bishop's broad experience as an operating officer within the pharmaceutical industry and his executive experience in the biotechnology industry, our Board believes Mr. Bishop has the appropriate set of skills to serve as our chief executive officer and a member of our Board.

Sunil Agarwal

Dr. Sunil Agarwal is President of Research & Development of the Company. Prior to joining us, Dr. Agarwal was a private equity partner at Sofinnova Ventures, a venture capital firm that focuses largely on life science investments, beginning in August 2016. From July 2014 to August 2016, he was executive vice president and chief medical officer at Ultragenyx Pharmaceutical Inc., clinical-stage biopharmaceutical company focused on the development of products for rare and ultra-rare disease, with a focus on serious, debilitating genetic diseases. From September 2003 to July 2014, Dr. Agarwal worked at Genentech Inc. in various positions of increasing responsibility, most recently as senior vice president, global development head for ophthalmology, metabolism, neuroscience, immunology, and infectious diseases. Dr. Agarwal serves on the board of directors of Calithera Biosciences, Inc. and MyoKardia Inc. Dr. Agarwal received a B.S. in Neurobiology from Cornell University in 1992 and an M.D. from Tufts University School of Medicine in 1996. Dr. Agarwal was a pediatric resident at Children's National Medical Center from 1996 to 1999.

Steven Harr

Dr. Steven D. Harr, M.D. serves as Chief Financial Officer, Head of Corporate Development of Juno Therapeutics Inc., since April 2014. Dr. Harr was managing director and head of Biotechnology Investment Banking at Morgan Stanley from May 2010 until he joined us. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley's lead biotech research analyst and co-head of global healthcare research. Dr. Harr serves on the board of directors of Loxo Oncology, Inc. Dr. Harr received a B.A. in Economics from the College of the Holy Cross in 1993 and an M.D. from The Johns Hopkins University School of Medicine in 1998. Dr. Harr was a resident in internal medicine at the University of California, San Francisco from 1998 to 2000.

Hyam Levitsky

Dr. Hyam Levitsky, M.D. serves as Executive vice president, research, chief scientific officer of the Company, since May 2015. Prior to joining us, Dr. Levitsky was head of cancer immunology experimental medicine at Roche Pharmaceuticals from August 2011 to February 2015. Dr. Levitsky has also been an adjunct professor of oncology, medicine, and urology at John Hopkins University School of Medicine since July 2001. Dr. Levitsky received a B.S. in Biomedical Engineering and Applied Science from the University of Pennsylvania in 1980 and an M.D. from The John Hopkins University School of Medicine in 1984. Dr. Levitsky was a resident in internal medicine at Johns Hopkins Hospital and was a senior clinical fellow in oncology at Johns Hopkins Oncology Center from 1985 to 1991.

Robert Azelby

Mr. Robert Azelby serves as Executive Vice President, Chief Commercial Officer of the Company. Prior to joining us, Mr. Azelby was vice president and general manager, oncology at Amgen Inc. from June 2012 to October 2015. From October 2010 to September 2012, he served as Amgen's vice president, Amgen Oncology Sales. Prior to that, he served in various positions at Amgen, including periods as vice president, commercial effectiveness unit and general manager of Amgen Netherlands. Mr. Azelby serves on the board of directors of Cascadian Therapeutics, Inc. Mr. Azelby received a B.A. in Economics and Religious Studies from the University of Virginia in 1990 and an M.B.A. from Harvard Business School in 1997.

Ann Lee

Dr. Ann Lee is Executive Vice President - Technical Operations of the Company. Prior to joining Juno, Dr. Lee held senior leadership positions at RocheGenentech, where she served as Senior Vice President and Global Head of Pharma Technical Development, and led a team of more than 2,500 professionals responsible for end-to-end chemistry, manufacturing and control (CMC), and technical support for all pipeline and commercial products. She also spent over 16 years at Merck & Co., Inc., where she led many of the company's vaccine development efforts and served as project leader for several vaccine products, including quadrivalent human papillomavirus vaccine. She also served as Vice President of Chemical Technology and Engineering in Merck's Manufacturing Division, where she directed the development, design and start-up of chemical manufacturing facilities, and led supply chain optimization and process improvements for new and licensed products.

Patrick Yang

Mr. Patrick Y. Yang is Executive Vice President of the Company. Mr. Yang had previously been Juno's interim leader for Technical Operations. Before serving in this role, Dr. Yang was Roche's Executive Vice President and Global Head of Technical Operations from 2010 to 2013. He was previously Executive Vice President, Product Operations of Genentech. Prior to joining Genentech in 2003, Dr. Yang spent 11 years at Merck & Company in various leadership positions including vice presidential roles in manufacturing and supply chain management. Dr. Yang also spent 12 years at General Electric, serving in various research, engineering, technology, and manufacturing leadership roles.

Bernard Cassidy

Mr. Bernard J. Cassidy serves as General Counsel, Secretary of Juno Therapeutics Inc., since January 2014. Prior to joining us, Mr. Cassidy served in various roles at Tessera Technologies, Inc., a semiconductor packaging company, from November 2008 to July 2013, including as its executive vice president, general counsel and secretary, and as president of Tessera Intellectual Property Corp. He served in various roles at Tumbleweed Communications Corp., a provider of secure messaging and secure file transfer solutions, from May 1999 to September 2008, including as its senior vice president, general counsel and secretary, with responsibility for legal, corporate development, and human resources matters. He practiced law at Wilson Sonsini Goodrich & Rosati, Professional Corporation, from August 1992 to May 1999, and at Skadden, Arps, Slate, Meagher & Flom LLP from September 1989 to July 1992. Mr. Cassidy received a B.A. in Philosophy from the Jesuit House of Studies, Loyola University, New Orleans in 1978, an M.A. in Philosophy from the University of Toronto in 1981, and a J.D. from Harvard Law School in 1988. He also completed the Executive Education Program for Growing Companies at Stanford Graduate School of Business in 2004.

Hal Barron

Dr. Hal V. Barron, M.D., serves as Independent Director of Juno Therapeutics Inc., since September 2014. Dr. Barron is currently the president of research and development at Calico Life Sciences LLC, a private biotechnology company, where he has been employed since November 2013. Previously, he served as executive vice president, head of global product development, and chief medical officer at Hoffmann-La Roche, or Roche, a global health care company, from January 2010 to November 2013. Dr. Barron was executive vice president at Genentech, which became a subsidiary of Roche in March 2009, from June 2009 to November 2013. While at Genentech, Dr. Barron also served as chief medical officer from June 2004 to November 2013, as senior vice president of development from June 2004 to June 2010, and as vice president of medical affairs from June 2002 to June 2004. Dr. Barron previously served as a member of the board of directors of Alexza Pharmaceuticals Inc., a public pharmaceutical company, from December 2007 to May 2013. He received a B.S. in engineering physics from Washington University in 1985 and an M.D. from Yale University in 1989. The Board believes that Dr. Barron's scientific and medical expertise, particularly in drug research and drug development, as well as his leadership in the biotechnology industry, make him an appropriate member of our Board.

Jay Flatley

Mr. Jay T. Flatley is Director of the company. He chairs the Board of Directors for an Illumina subsidiary, Helix. He is also an Advisory Board member for UC San Diego's Moore Cancer Center, serves on the Boards of Directors at Coherent and Denali, and is on the Board of Trustees of the Salk Institute. He previously served as President and Chief Executive Officer of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare. Mr. Flatley received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. (summa cum laude) in industrial engineering from Stanford University.

Richard Klausner

Dr. Richard Klausner, M.D. serves as Director at Juno Therapeutics, Inc. From September 2013 to February 2016, Dr. Klausner served first as senior vice president and chief medical officer and later as chief opportunity officer at Illumina Corporation, a publicly-traded biotechnology company. He served as the chairman of the board of directors of Audax Health until February 2014. Previously, he has served as managing partner of the venture capital firm, The Column Group from May 2005 to February 2011. Dr. Klausner was the executive director for global health of the Bill and Melinda Gates Foundation from 2002 to 2005 and was the eleventh director of the National Cancer Institute between 1995 and 2001. Dr. Klausner also served as chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development as well as a past president of the American Society of Clinical Investigation. Dr. Klausner is the chief strategy advisor for USAID and has served in senior advisory roles to the U.S., Norwegian, Qatari, and Indian governments. He previously chaired the International Advisory Board for Samsung and previously chaired the Strategic Oversight Council of Sanofi. Dr. Klausner received a B.S. in Molecular Biophysics and Biochemistry from Yale University in 1973 and an M.D. from Duke Medical School in 1976. The Board believes that Dr. Klausner's scientific and medical expertise, particularly in cell biology, molecular biology, and cancer, as well as his industry, academic, and public service leadership roles, make him an appropriate member of our Board.

Rupert Vessey

Dr. Rupert Vessey serves as Director of the Company. He has served as Celgene’s executive vice president and president, research and early development since January 2016. Dr. Vessey joined Celgene as its senior vice president, translational development in January 2015. Prior to Celgene, Dr. Vessey served in various positions at Merck over a period of ten years, most recently as its senior vice president of early development and discovery sciences. He is an elected Fellow of the Royal College of Physicians. Dr. Vessey graduated from Oxford University with a M.A. in Physiological Sciences, a BM BCh in Clinical Medicine, and a DPhil in Molecular Immunology. The Board believes that Dr. Vessey's extensive research and development experience, as well as his position at an important corporate partner and stockholder, makes him an appropriate member of our Board.

Thomas Daniel

Dr. Thomas O. Daniel, M.D., serves as Independent Director of Juno Therapeutics, Inc. Dr. Daniel has been the executive chairman of Vividion Therapeutics, a privately held biotechnology company, since February 2017 and executive director of Catalysis Advisors, a biotechnology consulting firm, since August 2016. He served as Celgene's chairman of Celgene research from January 2016 until June 2016, and was previously Celgene's president, research and early development from December 2006 to January 2016 and executive vice president and president, research and early development from February 2012 until July 2014. He served as the chief scientific officer and a member of the board of directors at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics, from 2003 to 2006. Dr. Daniel previously served as vice president, research at Amgen Inc., where he was research site head of Amgen Washington and therapeutic area head of inflammation. Prior to Amgen's acquisition of Immunex, Dr. Daniel served as senior vice president of discovery research at Immunex. Dr. Daniel has been a member of the therapeutic advisory board of aTyr Pharma, Inc., was previously a director for Epizyme Corporation, and is currently a director of Zafgen, Inc., Magenta Therapeutics, and VIR Therapeutics. Dr. Daniel serves as a member of the biomedical science advisory board of Vanderbilt University Medical Center and advises BlackThorn Therapeutics. He is a venture partner at ARCH Venture Partners. A nephrologist and former academic investigator, Dr. Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. Dr. Daniel received a B.A. from the Southern Methodist University in Texas in 1974 and an M.D. from the University of Texas, Southwestern, in 1978, and completed medical residency at Massachusetts General Hospital.

Anthony Evnin

Mr. Anthony B. Evnin, Ph.D., serves as an Independent Director of Juno Therapeutics Inc., since January 2014. Dr. Evnin is currently a member of the board of directors of AVEO Pharmaceuticals, Inc., Cantel Medical Corp., and Infinity Pharmaceuticals, Inc. as well as Bridge Medicines LLC and Constellation Pharmaceuticals, Inc., both private companies. Since 1975, Dr. Evnin has served as partner of Venrock, a venture capital firm, and has been employed by Venrock since 1974. Dr. Evnin was formerly a director of many other biotechnology companies, including Acceleron Pharma Inc., Celladon Corporation, Coley Pharmaceutical Group, Inc., Icagen, Inc., Pharmos Corp., and Sunesis Pharmaceuticals Incorporated. He serves as a trustee of The Jackson Laboratory, as a member of the boards of overseers and managers of Memorial Sloan Kettering Cancer Center, as a member of the board of directors of the New York Genome Center, as a member of the board of directors of the Albert and Mary Lasker Foundation, as a trustee emeritus of The Rockefeller University, and as a trustee emeritus of Princeton University. Dr. Evnin received an A.B. from Princeton University in 1962 and a Ph.D. in Chemistry from the Massachusetts Institute of Technology in 1966. The Board believes that Dr. Evnin's financial and investment expertise, scientific knowledge, and extensive service on public and private company boards, especially in life sciences, biotechnology and pharmaceutical industries, makes him an appropriate member of our Board.

Robert Nelsen

Dr. Robert T. Nelsen, M.D. serves as an Independent Director at Juno Therapeutics, Inc. Since 1994, Mr. Nelsen has served as a co-founder and managing director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies. Mr. Nelsen has played a significant role in the early sourcing, financing and development of more than 30 companies. Mr. Nelsen is a director of Sapphire Energy, Inc., Agios Pharmaceuticals Inc., Arivale, Inc., Denali Therapeutics, Inc., Ensemble Therapeutics Corporation, and Syros Pharmaceuticals, among other companies, and previously served as a director of Illumina, Inc., Fate Therapeutics, Inc., deCODE Genetics, Ltd., NeurogesX, Inc., KYTHERA Biopharmaceuticals, Inc., Bellerophon Therapeutics, Inc., Sage Therapeutics, Inc., and Caliper Life Sciences, Inc. Mr. Nelsen also previously served as a trustee of Fred Hutchinson Cancer Research Center. Mr. Nelsen received a B.S. in Economics and Biology from the University of Puget Sound in 1985 and an M.B.A. from the University of Chicago in 1987.

Mary Wilderotter

Mrs. Mary Agnes “Maggie” Wilderotter serves as an Independent Director of Juno Therapeutics Inc., since November 2014. From April 2015 to April 2016, Mrs. Wilderotter was executive chairman of the board of directors of Frontier Communications Corporation, a public telecommunications company formerly known as Citizens Communications Company. From November 2004 until April 2015, Mrs. Wilderotter was chief executive officer of Frontier and served as chairman of its board of directors since December 2005. Prior to joining Frontier, Mrs. Wilderotter was the senior vice president of the world wide public sector of Microsoft Corp. from November 2003 to November 2004 and the senior vice president of global business strategy of Microsoft from November 2002 to November 2003. From 1997 to 2002, Mrs. Wilderotter served as the president and chief executive officer of Wink Communications, an interactive telecommunications and media company. Mrs. Wilderotter is a member of the board of directors of two other public companies, Costco Wholesale Corporation and Hewlett Packard Enterprise Co. Mrs. Wilderotter previously served as a member of the board of directors of Dreamworks Animation SKG, Procter & Gamble, Xerox Corporation, and Yahoo! Inc. Mrs. Wilderotter received a B.A. in Economics from the College of the Holy Cross in 1977, an Honorary Doctor of Engineering from the Stevens Institute of Technology in 2014, and an Honorary Doctor of Laws from the University of Rochester in 2016. The Board believes that Mrs. Wilderotter's significant public company leadership experience as both a board member and an officer, her extensive business and financial acumen, and her deep expertise in marketing and technology make her an appropriate member of our Board.

Basic Compensation

Name Fiscal Year Total

Howard Pien

381,396

Hans Bishop

3,753,390

Sunil Agarwal

--

Steven Harr

2,915,660

Hyam Levitsky

2,129,150

Robert Azelby

1,912,220

Ann Lee

--

Patrick Yang

--

Bernard Cassidy

1,620,760

Hal Barron

356,038

Jay Flatley

--

Richard Klausner

598,890

Rupert Vessey

--

Thomas Daniel

100,000

Anthony Evnin

358,898

Robert Nelsen

354,154

Mary Wilderotter

365,882
As Of  31 Dec 2016